Personalized mRNA Cancer Vaccine Simulator | mRNA-4157 & Keytruda Mechanism

1. Patient Somatic Biopsy MEL-4157-08

HLA: HLA-A*02:01, A*24:02, B*07:02 | TMB: 14.2 mut/Mb

2. Synthetic mRNA Concatemer LNP Encapsulated

5' Cap

5' UTR

4 Neoepitopes

3' UTR

Poly(A)

Ionizable LNPs protect mRNA during vascular transit and facilitate endosomal escape inside dendritic antigen-presenting cells (APCs).

3. Lymph Node & Tumor Microenvironment In Vivo VACCINE_CONSTRUCT_ACTIVE

Zone 1: Dendritic Priming

Zone 2: Melanoma Tumor Bed

+ Pembrolizumab (Anti-PD-1) LNP Dose: 1.0mg

4. Immunological Telemetry Real-Time Kinetics

CD8+ T-Cell Expansion

18.6x

LNP Translation Eff.

92.5%

Tumor Lysis Rate

96.2%

Recurrence Hazard Ratio

0.56

5. Recurrence-Free Survival (RFS) Phase 2b Trial Data

mRNA-4157 + Keytruda (HR 0.56)

Keytruda Monotherapy

44% reduction in recurrence/death vs checkpoint inhibitor alone (Merck/Moderna Phase 2b KEYNOTE-942).